4-hydroxybenzo[b]thiophene-2-carbonitrile hyl 8-bromooctylphosphonate Smiles: C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CN)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](C)C(O)=O

Smiles: C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CN)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](C)C(O)=O

CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1

TMPA may serve as a powerful chemical tool to attain a mechanistic understanding of the regulation of LKB1-AMPK axis and a lead compound for the design and development of therapeutics to treat metabolic diseases

the half-life of OR-1896 is about 75 to 80 h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan

4-hydroxybenzo[b]thiophene-2-carbonitrile hyl 8-bromooctylphosphonate Smiles: C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CN)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](C)C(O)=OProduct information CAS Number: 476199 30 1 Molecular Weight: 175. 21 Formula: C9H5NOS Chemical Name: 4 hydroxy 1 benzothiophene 2 carbonitrile Smiles: N#CC1=CC2=C(O)C=CC=C2S1 InChiKey: JTDFGDNWJPUOGH UHFFFAOYSA N InChi: InChI=1S C9H5NOS c10 5 6 4 7 8(11)2 1 3 9(7)12 6 h1 4,11H Technical Data Appearance: Solid Power Purity: 98% (or refer to the Certificate of Analysis) Solubility: To be determined Shipping Condition: Shipped under ambient temperature